Overview

Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors

Status:
Completed

Trial end date:
2004-04-22

Target enrollment:

Participant gender:

Summary

RATIONALE: Erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining erlotinib with gemcitabine may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining erlotinib with gemcitabine in treating patients who have newly diagnosed locally advanced or metastatic pancreatic cancer or other solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

OSI Pharmaceuticals

Collaborator:

National Cancer Institute (NCI)

Treatments:

Erlotinib Hydrochloride
Gemcitabine